ZD1694 ('Tomudex'*) is a novel quinazoline anti-folate, developed in a collaborative research programme. The goal of the programme was to identify direct and specific inhibitors of thymidylate synthase (TS), thus avoiding the non-specific effects (upon protein synthesis and RNA) of agents such as methotrexate (MTX) and 5-fluorouracil (5FU) which are believed to play a role in the toxicity profiles (leucopenia, mucositis) of these drugs. ZD1694 undergoes extensive intracellular polyglutamation (Jackman et al., 1993) . This effectively causes it to be retained within the cell and therefore allows a convenient intermittent (3 weekly) schedule. Preclinical data and phase I data indicated activity in breast cancer, and a phase I study defined a recommended dose of 3.0 mg m-2, i.v. 3 weekly, with dose-limiting toxicities of leucopenia, diarrhoea, tiredness/asthenia and self-limited asymptomatic rises in transaminase levels (Clarke et al., 1994 WHO and UICC recommendations (World Health Organization, 1979; Hayward et al., 1977) for measurable and evaluable lesions, and for objective response were used. The study was designed such that recruitment of 40 patients to the study would provide 92% power to detect a response rate of 20%. A one-sample multiple testing procedure was used during patient accrual to allow for early termination of the trial if initial results were extreme (Fleming, 1982) .
Pretreatment evaluations included full clinical examination, objective tumour assessment, haematology and biochemistry. Haematology and toxicity assessment was performed weekly, biochemistry 3 weekly and objective response assessment 6 weekly during the conduct of the study. Table IV . Increases in urea and creatinine levels were grade 1 and appeared to be related to volume depletion after diarrhoea or vomiting. Cutaneous effects and alopecia were unusual.
Three patients died from possible drug-related events during the study; two of these patients had experienced substantial gastrointestinal and haematological toxicity with the previous cycle and had not received appropriate dose modification. One of these two patients died of pneumonia, for which she was not actively treated. The second died from aA 40-49% decrease in sum of area of lesions. gastrointestinal haemorrhage associated with disseminated intravascular coagulation. The third patient died with a combination of gastrointestinal and haematological toxicity.
Discussion
ZD1694 is a quinazoline anti-folate developed during a rational drug design and research collaboration between the Institute of Cancer Research and Zeneca Pharmaceuticals (Jackman et al., 1993) . It is a potent, direct and specific inhibitor of TS and was predicted to offer toxicity benefits owing to the lack of non-specific, non-TS effects on RNA and purine metabolism that are seen with drugs such as MTX and 5FU. ZD1694 undergoes intracellular polyglutamation with the formation of potent polyglutamates allowing prolonged drug action (Jackman et al., 1993) . A convenient single-dose intermittent (3 weekly) schedule is therefore appropriate. This schedule was confirmed in a phase I study with the drug, which defined a maximum tolerated dose (MTD) of 3.5 mg m-2. A dose of 3.0 mg m-2 was recommended for phase II studies (Clarke et al., 1994) . Dose-limiting and doserelated toxicities in phase I studies were haematological (reversible leucopenia), gastrointestinal (diarrhoea), tiredness or asthenia, and reversible self-limited rises in liver transaminases.
Based on the dosing and scheduling recommendations from the phase I study, a phase II programme was initiated in eight tumour types. These included studies in platinum refractory ovarian cancer, previously treated small-cell lung cancer and gastric cancer, previously untreated colorectal cancer, pancreatic, hepatocellular and non-small-cell lung cancer, and as first-line chemotherapy for advanced breast cancer. While objective responses have been reported in a range of tumour types , the most interesting activity, apart from that seen in breast cancer, has been seen in colorectal cancer (Adenis et al., 1994) , with final response rates in a large (177 patients) phase II study being 26% (95% CI 19-33%). The drug is now completing international phase III studies in this indication.
This report describes the phase II study conducted in 46 patients, many of whom had hormone-refractory advanced breast cancer or had received adjuvant cytotoxic chemotherapy. The overall objective response rate in this study was 26% (95% CI 14-42%). Two patients achieved sustained CRs, (265-301 days), and one of these patients had a second sustained CR when rechallenged after relapse. Of interest, there was a high response rate (44%) in patients with measurable liver lesions. ZD1694 was in general well tolerated, with 85% of the patients able to receive their scheduled dose of ZD1694 without significant delay or modification. The most frequently reported adverse events were self-limited increases in liver transaminases, leucopenia and diarrhoea. Alopecia was remarkable for its low incidence.
The response rate in this study compares favourably with reported response rates in the older literature using less stringent response criteria (Hoogstraten and Fabian, 1979) for other anti-metabolites such as MTX and 5FU. Studies with other agents such as paclitaxel and docetaxel have reported response rates of between 30% and 67% in small phase II studies but may be associated with significant toxicity, including hypersensitivity, bone marrow suppression, fluid retention, pruritis and myalgia (Gianni et al., 1994; Chevallier et al., 1995) .
ZD1694 is the product of a rational drug design programme and has useful activity in advanced hormonerefractory breast cancer. The acceptable safety profile suggests that further studies with the drug in combination chemotherapy regimens are appropriate, and in particular as a substitute for methotrexate and or 5-fluorouracil.
